Share This Author
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Evaluated data suggest that MPDL3280A is most effective in patients in which pre-existing immunity is suppressed by PD-L1, and is re-invigorated on antibody treatment, as well as across multiple cancer types.
Pembrolizumab for the treatment of non-small-cell lung cancer.
Pembrolizumab had an acceptable side-effect profile and showed antitumor activity in patients with advanced non-small-cell lung cancer and PD-L1 expression in at least 50% of tumor cells correlated with improved efficacy of pembrolIZumab.
Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer
Osimertinib showed efficacy superior to that of standard EGFR‐TKIs in the first‐line treatment of EGFR mutation–positive advanced NSCLC, with a similar safety profile and lower rates of serious adverse events.
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
It is found that primary resistance to ICIs can be attributed to abnormal gut microbiome composition, and Antibiotics inhibited the clinical benefit of ICIs in patients with advanced cancer.
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer
This study implicates histone modification as a major feature of SCLC, reveals potentially therapeutically tractable genomic alterations and provides a generalizable framework for the identification of biologically relevant genes in the context of high mutational background.
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.
- S. Ramalingam, J. Vansteenkiste, J. Soria
- Medicine, BiologyThe New England journal of medicine
- 21 November 2019
Among patients with previously untreated advanced NSCLC with an EGFR mutation, those who received osimertinib had longer overall survival than those whoreceived a comparator EGFR-TKI.
DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.
Patients with completely resected non-small-cell lung cancer and ERCC1-negative tumors appear to benefit from adjuvant cisplatin-based chemotherapy, whereas patients with ER CC1-positive tumors do not.
Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
A novel aggressive pattern of hyperprogressive disease or HPD exists in a fraction of patients treated with anti-PD-1/PD-L1 monotherapy, and this observation raises some concerns about treating elderly patients (>65 years old), and suggests further study of this phenomenon.
Immune-related adverse events with immune checkpoint blockade: a comprehensive review.